{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:32:35Z","timestamp":1791379955758,"version":"4.3.3"},"reference-count":46,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2001,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To assess the relationship between venous thrombosis and plasma glucosylceramide (GlcCer) or phosphatidylethanolamine (PE), plasma levels of GlcCer and PE were determined for 70 venous thrombosis patients referred for evaluation and 70 healthy blood donors. The mean GlcCer level, but not the PE level, was lower in patients versus controls (4.9 vs 6.5 \u03bcg\/mL [P\u2009=\u2009.0007] and 66 vs 71 \u03bcg\/mL [P\u2009=\u2009.48], respectively). As a measure of relative risk, the odds ratio for deep vein thrombosis in subjects with GlcCer levels below the 10th percentile of controls was 5.7 (95% CI, 2.3-14). To assess the influence of glycolipids on anticoagulant response to activated protein C (APC):protein S in modified prothrombin time assays, the effects of depleting endogenous plasma GlcCer by glucocerebrosidase treatment or of adding exogenous purified GlcCer or other neutral glycolipids to plasma were tested. Glucocerebrosidase treatment reduced plasma sensitivity to APC:protein S in parallel with GlcCer reduction. Exogenously added GlcCer and the homologous Glc-containing globotriaosylceramide (Gb3Cer), but not galactosylceramide, dose-dependently prolonged clotting times of normal plasma in the presence, but not absence, of APC:protein S, which suggests that GlcCer or Gb3Cer can enhance protein C pathway anticoagulant activity. In studies using purified proteins, inactivation of factor Va by APC:protein S was enhanced by GlcCer alone and by GlcCer in multicomponent vesicles containing phosphatidylserine and phosphatidylcholine. These results suggest that the neutral glycolipids GlcCer and Gb3Cer may directly contribute to the anticoagulant activity of the protein C pathway and that deficiency of plasma GlcCer may be a risk factor for venous thrombosis.<\/jats:p>","DOI":"10.1182\/blood.v97.7.1907","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T12:46:40Z","timestamp":1027774000000},"page":"1907-1914","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":45,"title":["Plasma glucosylceramide deficiency as potential risk factor for venous thrombosis and modulator of anticoagulant protein C pathway"],"prefix":"10.1182","volume":"97","author":[{"given":"Hiroshi","family":"Deguchi","sequence":"first","affiliation":[{"name":"From the Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA; the First Department of Medicine, University of Vienna, Austria; and the Department of Medicine, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose\u0301A.","family":"Ferna\u0301ndez","sequence":"additional","affiliation":[{"name":"From the Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA; the First Department of Medicine, University of Vienna, Austria; and the Department of Medicine, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Pabinger","sequence":"additional","affiliation":[{"name":"From the Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA; the First Department of Medicine, University of Vienna, Austria; and the Department of Medicine, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Heit","sequence":"additional","affiliation":[{"name":"From the Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA; the First Department of Medicine, University of Vienna, Austria; and the Department of Medicine, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Griffin","sequence":"additional","affiliation":[{"name":"From the Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA; the First Department of Medicine, University of Vienna, Austria; and the Department of Medicine, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021217395148600_B1","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJM199402243300801","article-title":"Resistance to activated protein C as a basis for venous thrombosis.","volume":"330","author":"Svensson","year":"1994","journal-title":"N Engl J Med."},{"key":"2020021217395148600_B2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0049-3848(96)00070-9","article-title":"Clinical significance of activated protein C resistance as a potential marker for hypercoagulable state.","volume":"82","author":"Sakata","year":"1996","journal-title":"Thromb Res."},{"key":"2020021217395148600_B3","doi-asserted-by":"crossref","first-page":"643","DOI":"10.7326\/0003-4819-130-8-199904200-00004","article-title":"Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism.","volume":"130","author":"Rodeghiero","year":"1999","journal-title":"Ann Intern Med."},{"key":"2020021217395148600_B4","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1182\/blood.V93.4.1271","article-title":"A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis.","volume":"93","author":"de Visser","year":"1999","journal-title":"Blood."},{"key":"2020021217395148600_B5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/369064a0","article-title":"Mutation in blood coagulation factor V associated with resistance to activated protein C.","volume":"369","author":"Bertina","year":"1994","journal-title":"Nature."},{"key":"2020021217395148600_B6","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/S0140-6736(94)92497-X","article-title":"Activated protein C resistance caused by Arg506Gln mutation in factor Va.","volume":"343","author":"Greengard","year":"1994","journal-title":"Lancet."},{"key":"2020021217395148600_B7","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(94)92939-4","article-title":"Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V.","volume":"343","author":"Voorberg","year":"1994","journal-title":"Lancet."},{"key":"2020021217395148600_B8","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/S0140-6736(99)06092-4","article-title":"Low-dose oral contraceptives and acquired resistance to activated protein C.","volume":"354","author":"Rosing","year":"1999","journal-title":"Lancet."},{"key":"2020021217395148600_B9","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood.V94.3.895.415k01_895_901","article-title":"Extensive venous and arterial thrombosis associated with an inhibitor to activated protein C.","volume":"94","author":"Zivelin","year":"1999","journal-title":"Blood."},{"key":"2020021217395148600_B10","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1161\/01.STR.27.7.1163","article-title":"Activated protein C resistance in ischemic stroke not due to factor V arginine506\u2014&gt;glutamine mutation.","volume":"27","author":"Fisher","year":"1996","journal-title":"Stroke."},{"key":"2020021217395148600_B11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.7326\/0003-4819-125-4-199608150-00002","article-title":"Reduced response to activated protein C is associated with increased risk for cerebrovascular disease.","volume":"125","author":"van der Bom","year":"1996","journal-title":"Ann Intern Med."},{"key":"2020021217395148600_B12","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S0140-6736(83)91216-3","article-title":"Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant.","volume":"2","author":"Branson","year":"1983","journal-title":"Lancet."},{"key":"2020021217395148600_B13","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1056\/NEJM198403013100904","article-title":"Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn.","volume":"310","author":"Seligsohn","year":"1984","journal-title":"N Engl J Med."},{"key":"2020021217395148600_B14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0140-6736(90)90201-F","article-title":"Neonatal purpura fulminans associated with homozygous protein S deficiency.","volume":"335","author":"Mahasandana","year":"1990","journal-title":"Lancet."},{"key":"2020021217395148600_B15","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1172\/JCI3011","article-title":"Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice.","volume":"102","author":"Jalbert","year":"1998","journal-title":"J Clin Invest."},{"key":"2020021217395148600_B16","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood.V59.5.1067.1067","article-title":"Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme.","volume":"59","author":"Marlar","year":"1982","journal-title":"Blood."},{"key":"2020021217395148600_B17","doi-asserted-by":"crossref","first-page":"10363","DOI":"10.1021\/bi00107a001","article-title":"The coagulation cascade: initiation, maintenance, and regulation.","volume":"30","author":"Davie","year":"1991","journal-title":"Biochemistry."},{"key":"2020021217395148600_B18","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0021-9258(17)42183-1","article-title":"Phosphatidylethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated protein C.","volume":"269","author":"Smirnov","year":"1994","journal-title":"J Biol Chem."},{"key":"2020021217395148600_B19","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1021\/bi982538b","article-title":"The effect of membrane composition on the hemostatic balance.","volume":"38","author":"Smirnov","year":"1999","journal-title":"Biochemistry."},{"key":"2020021217395148600_B20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1006\/bcmd.2000.0285","article-title":"Cardiolipin enhances protein C pathway anticoagulant activity.","volume":"26","author":"Ferna\u0301ndez","year":"2000","journal-title":"Blood Cells Mol Dis."},{"key":"2020021217395148600_B21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1172\/JCI5006","article-title":"High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C.","volume":"103","author":"Griffin","year":"1999","journal-title":"J Clin Invest."},{"key":"2020021217395148600_B22","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0022-2275(20)36996-0","article-title":"Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias.","volume":"17","author":"Dawson","year":"1976","journal-title":"J Lipid Res."},{"key":"2020021217395148600_B23","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/oxfordjournals.jbchem.a124992","article-title":"Functional role of glycosphingolipids in cell recognition and signaling.","volume":"118","author":"Hakomori","year":"1995","journal-title":"J Biochem."},{"key":"2020021217395148600_B24","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1042\/bj1040340","article-title":"Lipid composition of human serum lipoproteins.","volume":"104","author":"Skipski","year":"1967","journal-title":"Biochem J."},{"key":"2020021217395148600_B25","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1073\/pnas.97.4.1743","article-title":"Cardiolipin is a normal component of human plasma lipoproteins.","volume":"97","author":"Deguchi","year":"2000","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2020021217395148600_B26","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0076-6879(81)72012-3","article-title":"Thin-layer chromatography of neutral glycosphingolipids and gangliosides.","volume":"72","author":"Kundu","year":"1981","journal-title":"Methods Enzymol."},{"key":"2020021217395148600_B27","doi-asserted-by":"crossref","first-page":"30271","DOI":"10.1074\/jbc.273.46.30271","article-title":"Lysosomal degradation on vesicular membrane surfaces: enhanced glucosylceramide degradation by lysosomal anionic lipids and activators.","volume":"273","author":"Wilkening","year":"1998","journal-title":"J Biol Chem."},{"key":"2020021217395148600_B28","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1139\/o81-057","article-title":"The glycosphingolipids of human plasma lipoproteins.","volume":"59","author":"Clarke","year":"1981","journal-title":"Can J Biochem."},{"key":"2020021217395148600_B29","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1161\/01.ATV.18.10.1523","article-title":"Sphingolipids in atherosclerosis and vascular biology.","volume":"18","author":"Chatterjee","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"2020021217395148600_B30","doi-asserted-by":"crossref","first-page":"31869","DOI":"10.1016\/S0021-9258(18)31776-9","article-title":"The mechanism of inactivation of human factor V and human factor Va by activated protein C.","volume":"269","author":"Kalafatis","year":"1994","journal-title":"J Biol Chem."},{"key":"2020021217395148600_B31","doi-asserted-by":"crossref","first-page":"27852","DOI":"10.1074\/jbc.270.46.27852","article-title":"Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C.","volume":"270","author":"Rosing","year":"1995","journal-title":"J Biol Chem."},{"key":"2020021217395148600_B32","doi-asserted-by":"crossref","first-page":"14884","DOI":"10.1016\/S0021-9258(18)68121-9","article-title":"Kinetics of inactivation of membrane-bound factor Va by activated protein C: protein S modulates factor Xa protection.","volume":"263","author":"Solymoss","year":"1988","journal-title":"J Biol Chem."},{"key":"2020021217395148600_B33","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1002\/pro.5560050914","article-title":"Binding sites for blood coagulation factor Xa and protein S involving residues 493-506 in factor Va.","volume":"5","author":"Heeb","year":"1996","journal-title":"Protein Sci."},{"key":"2020021217395148600_B34","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1182\/blood.V93.8.2552","article-title":"Cleavage of factor V at Arg506 by activated protein C and expression of anticoagulant activity of factor Va.","volume":"93","author":"Thorelli","year":"1999","journal-title":"Blood."},{"key":"2020021217395148600_B35","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1055\/s-2007-1002786","article-title":"Vitamin K-dependent proteins bind to very low-density lipoproteins.","volume":"14","author":"Bradley","year":"1988","journal-title":"Semin Thromb Hemost."},{"key":"2020021217395148600_B36","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/01.ATV.18.3.458","article-title":"Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes.","volume":"18","author":"Moyer","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"2020021217395148600_B37","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1161\/01.ATV.18.1.33","article-title":"Association of vitamin K-dependent coagulation proteins and C4b binding protein with triglyceride-rich lipoproteins of human plasma.","volume":"18","author":"Xu","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"2020021217395148600_B38","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1365-2141.1999.01302.x","article-title":"Acquired APC resistance and oral contraceptives: differences between two functional tests.","volume":"105","author":"Curvers","year":"1999","journal-title":"Br J Haematol."},{"key":"2020021217395148600_B39","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1365-2141.1995.tb05610.x","article-title":"Development of resistance to activated protein C during pregnancy.","volume":"90","author":"Cumming","year":"1995","journal-title":"Br J Haematol."},{"key":"2020021217395148600_B40","first-page":"F24","article-title":"Control of kidney size by sex hormones: possible involvement of glucosylceramide.","volume":"262","author":"Shukla","year":"1992","journal-title":"Am J Physiol."},{"key":"2020021217395148600_B41","first-page":"589","article-title":"Chemotherapy by slowing glucosphingolipid synthesis.","volume":"57","author":"Radin","year":"1999","journal-title":"Biochem Pharmacol."},{"key":"2020021217395148600_B42","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0014-5793(96)00942-8","article-title":"Tamoxifen retards glycosphingolipid metabolism in human cancer cells.","volume":"394","author":"Cabot","year":"1996","journal-title":"FEBS Lett."},{"key":"2020021217395148600_B43","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1046\/j.1365-2125.1998.00733.x","article-title":"Tamoxifen and risk of idiopathic venous thromboembolism.","volume":"45","author":"Meier","year":"1998","journal-title":"Br J Clin Pharmacol."},{"key":"2020021217395148600_B44","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1056\/NEJM199905203402007","article-title":"Vascular-bed specific hemostasis and hypercoagulable states.","volume":"340","author":"Rosenberg","year":"1999","journal-title":"N Engl J Med."},{"key":"2020021217395148600_B45","doi-asserted-by":"crossref","first-page":"8215","DOI":"10.1016\/S0021-9258(20)82051-1","article-title":"Sulfatide-dependent autoactivation of human blood coagulation factor XII (Hageman factor).","volume":"258","author":"Tans","year":"1983","journal-title":"J Biol Chem."},{"key":"2020021217395148600_B46","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/oxfordjournals.jbchem.a124118","article-title":"Anticoagulant activity of sulfatide and its antithrombotic effect in rabbit.","volume":"113","author":"Hara","year":"1993","journal-title":"J Biochem."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/97\/7\/1907\/1672132\/h8070101907.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/97\/7\/1907\/1672132\/h8070101907.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T09:20:45Z","timestamp":1622020845000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/97\/7\/1907\/53379\/Plasma-glucosylceramide-deficiency-as-potential"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,4,1]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2001,4,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.v97.7.1907","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2001,4,1]]}}}